David Nayagam from E & P covers PYC. Has release a speculative buy note out today with a 24c valuation. He notes "developmental molecular therapies targeting monogenic conditions with clear genotypic-phenotypic associations enjoy tantalizingly high probabilities of success". Still adopts a conservative approach to the current valuation and ascribes zero value to the third and fourth pipeline assets (PM and PKD).
Ann: Investor Presentation ADOA Program, page-25
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 82937 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 3000 | 1 |
View Market Depth
| Last trade - 09.07am 17/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |
Day chart unavailable